Blog

RECALL ALERT: Auvi-Q

Sanofi US Issues Voluntary Nationwide Recall of Auvi‑Q®
Due to Potential Inaccurate Dosage Delivery

Sanofi US is voluntarily recalling all Auvi-Q® (epinephrine injection, USP).

 The recall involves all Auvi-Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016. The products have been found to potentially have inaccurate dosage delivery.

 As of October 26, 2015, Sanofi has received 26 reports of suspected device malfunctions in the US and Canada. None of these device malfunction reports have been confirmed. In these reports, patients have described symptoms of the underlying hypersensitivity reaction. No fatal outcomes have been reported among these cases.

Customers with questions regarding this recall can go to www.Auvi-Q.com and call 1-866-726-6340 Monday through Friday 8 a.m. to 8 p.m. ET for information about how to return their Auvi-Q devices. Customers may also email cs@sanofi.com. Sanofi US will provide reimbursement for out of pocket costs incurred for the purchase of new epinephrine auto-injectors with proof of purchase.

TAGS     auvi-q,  epi-pen,  allergies,  anaphylaxis,  recall,  epinephrine injection,  sanofi US,  
Link to Blog Entry:
 

E-mail to a FriendFacebookTweet This

About the Author

I am a board certified pediatric nurse practitioner and nationally certified as a massage therapist. I hold certificates in aromatherapy and as a certified infant massage instructor. I have a strong interest in the effects of aromatherapy and essential oils on health care...